Clinical Trial Update: Japanese Phase 1 Study of BMS-844203 (CT322) [Phase 1]

View source ↗

Summary

A Japanese Phase 1 trial of Bristol-Myers Squibb's BMS-844203 (CT322) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• BMS-844203 (CT322) (BMS-844203)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Neoplasms | Phase 1 | Status: WITHDRAWN